CytoNiche Biotech has inaugurated its 3D FloTrix Experience Hub in Singapore, marking a significant milestone in its global expansion strategy. The hub showcases the company’s cutting-edge 3D cell production technology, which supports China’s first approved stem cell drug at a fraction of the cost of Western alternatives.
The new facility addresses the global challenge of high mesenchymal stem cell therapy costs. In the US, the first FDA-approved stem cell therapy is priced at $1.55 million per treatment, whereas China’s Amimestrocel Injection costs approximately $21,600 per course. This cost efficiency is achieved through CytoNiche’s 3D FloTrix platform, which utilises automated, scalable 3D cell production systems with GMP-grade dissolvable microcarriers, moving away from traditional 2D methods.
The Singapore hub will serve as a global headquarters, technology demonstration centre, and training facility for international partners. It aims to promote cost-effective stem cell manufacturing and support regulatory and clinical advancements in Asia and beyond. Dr. Yan Xiaojun, CTO and Co-Founder of CytoNiche, highlighted Singapore’s strategic location and robust biotech ecosystem as ideal for global outreach.
At the opening ceremony, Dr. Yan reflected on CytoNiche’s journey since its founding in 2018, culminating in the approval of China’s first stem cell drug. Professor Hanry Yu of the National University of Singapore praised the company’s international collaboration efforts.
Looking ahead, CytoNiche plans to expand its international presence and further reduce barriers to cell-based therapies through automated biomanufacturing platforms. Professor Du Yanan, Chief Scientist at CytoNiche, emphasised the hub’s role in making regenerative medicine more accessible worldwide.
“`
